Jennifer Croden

8PUBLICATIONS
32CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Medical mycologyCardiovascular medicine and haematology not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Mar 30, 2026
A phase I open label study of fostamatinib, a SYK inhibitor, in patients with lower-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

J Croden, G Garcia-Manero, K Chien

|Feb 16, 2026
Outcomes of therapy-related non-core binding factor acute myeloid leukemia with venetoclax-based therapies.

Jayastu Senapati, Jennifer Croden, Guillermo Garcia-Manero

|Feb 13, 2026
Clinical, genetic, and familial features of POT1 tumor predisposition syndrome.

Courtney D DiNardo, Jennifer Croden, Hiam M Abdel-Salam

|Oct 24, 2025
A Phase 2 study of CPX-351 in combination with venetoclax in patients with newly diagnosed high-risk acute myeloid leukemia.

Wei-Ying Jen, Jennifer Croden, Emmanuel Almanza-Huante

|Sep 22, 2025
MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia.

Wei-Ying Jen, Guilin Tang, Eitan Kugler

|Dec 02, 2021
Incidence of bleeding and thromboembolism and impact on overall survival in adult patients with hemophagocytic lymphohistiocytosis: A 20-year provincial retrospective cohort study.

Jennifer Croden, Lisa Bilston, Minakshi Taparia

Pageof 2

Frequent Collaborators

4 joint publications

Tapan M Kadia

3 joint publications

Courtney D DiNardo

3 joint publications

Hagop M Kantarjian

2 joint publications

Kelly S Chien